Your Article Summary
See Latest ArticlesGranulocyte Macrophage-Colony Stimulating Factor Plus Interleukin-2 Plus [alpha]-interferon Plus 5-Fluorouracil in the Treatment of Metastatic Renal Cell Cancer: Induction of CD80/86+ T Cells Indicates Adverse Outcome
Journal of Immunotherapy, 06/24/09
Westermann J et al. - Clinical response rates of this cytokine-based regimen do not justify further clinical evaluation. However, the study suggests that CD80/86+ T cells might have negative regulatory function under cytokine treatment and are possibly useful as a negative predictive marker for clinical response.
Today in Hematology/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of distant metastasis and peripheral CA 15-3 on the induction of spontaneous T cell responses in breast cancer patients
Cancer Immunology, Immunotherapy, 12/14/09
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/14/09
Today in Nephrology/Urology...keeping you current
Receive free subspecialty "5-minute updates" via email
Reduction of the Occurrence of Acute Cellular Rejection Among Renal Allograft Recipients Treated With Basiliximab, A Chimeric Anti-Interleukin-2-Receptor Monoclonal Antibody
Transplantation, 12/15/09
Mycoplasma genitalium-Derived Lipid-Associated Membrane Proteins Activate NF-B through Toll-Like Receptors 1, 2, and 6 and CD14 in a MyD88-Dependent Pathway
Clinical and Vaccine Immunology, 12/10/09